Galmed pharmaceuticals ltd. (nasdaq: glmd) announces receipt of extension to meet the nasdaq's minimum bid price requirement

Tel aviv, israel , dec. 14, 2022 /prnewswire/ -- galmed pharmaceuticals ltd. (nasdaq: glmd) ("galmed" or the "company"), a biopharmaceutical company focused on the development of aramchol and amilo-5mer, announced today that on december 13, 2022, it received a letter from the nasdaq stock market llc ("nasdaq"), notifying the company that it is eligible for an additional 180 calendar day period, or until june 12, 2023, to regain compliance with the nasdaq's minimum $1 bid price per share requirement.
GLMD Ratings Summary
GLMD Quant Ranking